Tag: Dr. Reddy’s Laboratories
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a ... Read More
Dr. Reddy’s Laboratories rolls out Regadenoson Injection in US
Indian pharma company Dr. Reddy's Laboratories said that it has launched Regadenoson Injection 0.4 mg/5 mL in the US market. Approved by the US Food ... Read More
Eris Lifesciences strikes deal for Dr. Reddy’s cosmetic dermatology brands
Eris Lifesciences has announced the acquisition of nine cosmetic dermatology brands in the Indian market from Dr. Reddy's Laboratories for INR 275 crores in cash. ... Read More
Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio
Dr. Reddy's Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth ... Read More
Dr Reddy’s Labs announces limited volume US launch of Lenalidomide Capsules
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved ... Read More
Dr. Reddy’s Labs, Slayback sign licensing deal for Brimonidine Tartrate
Dr. Reddy’s Laboratories said that it has signed a licensing deal with New Jersey-based Slayback Pharma for acquiring rights in the latter’s Brimonidine Tartrate Ophthalmic ... Read More
Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US
Dr. Reddy’s Laboratories has launched Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets in the US market following the approval of the US Food and Drug Administration ... Read More
Dr. Reddy’s Laboratories launches sorafenib generic in US
Dr. Reddy’s Laboratories said that it has launched Dr. Reddy’s Sorafenib Tablets, USP, 200 mg in the US market following the approval of the US ... Read More
Dr. Reddy’s subsidiary Aurigene signs $438m licensing deal with Olema
Dr. Reddy’s Laboratories said that its fully-owned subsidiary Aurigene Discovery Technologies has signed an exclusive global collaboration and license agreement worth up to $438 million ... Read More
Torrent Pharma buys Styptovit-E, Finast, and other brands from Dr. Reddy’s
Torrent Pharmaceuticals has agreed to acquire the Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr. Reddy's Laboratories for an undisclosed price. Styptovit-E is a gynecology ... Read More